The Diagnosed Dead Is Far from Dying Xoma (XOMA): Stock rallied following report announcing an upfront …

As we kept describing it, Illumina’s (ILMN) is the engine behind the biological revolution reflected in the current …

Preparing a Prohost Letter dedicated to immunotherapy and the firms that are behind the promising novel …

Exelixis’ (EXEL) quarterly results beat analysts’ expectations, which was the least of our concerns. The details of the …

Baxalta (BXLT) and Precision BioSciences a genome editing company announced a global collaboration to develop a broad …

AMGEN AND OSTEOPOROSIS Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study of Romosozumab …

Regulus Pharmaceuticals (RGLS) a biopharmaceutical company that discovers, designs and develop treatments targeting microRNAs announced interim results from one …

Yes. Dana-Farber Cancer Institute and Array Pharmaceuticals (ARRY) announced an immuno-oncology collaboration with potential applicability in a wide …

Incyte: A Good Company Facing Irrelevant Investors’ Reaction  Incyte decided to stop an early ongoing trial …

Halozyme Therapeutics (HALO) seems to have closed the previously announced $150 million royalty-backed debt transaction with investment …